Navigation Links
Isolagen, Inc. Postpones Annual Meeting
Date:9/24/2007

EXTON, Pa., Sept. 24 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today that it is postponing its 2007 Annual Meeting of Stockholders scheduled for tomorrow in Nashville, Tennessee in order to obtain a quorum of shareholder votes. The company has rescheduled the annual meeting for Monday, November 5, 2007 at 1:00 p.m. in Philadelphia, Pennsylvania.

The record date for stockholders entitled to vote at the meeting remains the close of business on September 5, 2007. Stockholders who have previously sent in proxy cards or given instructions to brokers do not need to recast their votes.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as well as other public filings with the SEC since such date.


'/>"/>
SOURCE Isolagen(TM), Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AIIMS Postpones Semester Exam due to Dengue Outbreak
2. Annual PSA screening reduces risk of prostate cancer deaths
3. Low turnover by Diabetics for free annual checkup
4. UK Spends ?7.3 Billion Annually On Malnutrition Cost
5. Annual Dental Checkups in Children Lagging Behind
6. Annual Budget 2006: Health And Education Sector Receive A Boost
7. Breast cancer survivors slacken on mandated annual mammograms
8. Brazil & Kenya Seek Support For A New Resolution At WHO’s Annual Mee
9. Medical Tourism can Fetch Rs.100 bn Annually by 2012
10. Annual Conference Of Plastic Surgeons In US To Focus On The Future Of Plastic Surgery
11. Jamaica Sees 1000 New Cases of HIV Annually
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... today with a new Indiegogo campaign . Individuals are now able to contribute ... Los Angeles area, either as a participating patient or through an Indiegogo donation. The ...
(Date:2/23/2017)... ... 2017 , ... Carlos Gutierrez has lived his spiritual life hardly ... which is the purpose of everyone in this universe. As Gutierrez sees the need ... Press) attempts to guide readers to expand one’s spiritual life. , “Our Spiritual Truths” ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem ... recent years. The technology is so cutting edge, in fact, the U.S. Food ... stem cell procedures. However, successful patient outcomes in certain clinical stem cell procedures ...
(Date:2/22/2017)... Northbrook, IL (PRWEB) , ... February 22, 2017 , ... ... stories, is proud to once again feature Heroes On The Water (HOW), a non-profit ... This season’s all new episode has series host ‘Mike D’ traveling to Lake Denmark, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)...  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... fourth quarter and full year 2016 financial results on Thursday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at 4:30 ... be obtained as follows: Thursday, March 2 ...
(Date:2/22/2017)... N.J. , Feb. 22, 2017  Andre, DiMino, ... technology-based developer and manufacturer of innovative technologies and products, ... results reported on February 21, 2017 in the Company,s ... . ADMT CEO Andre, DiMino stated "During ... our business plan by devoting a larger portion of ...
(Date:2/22/2017)... -- Ultra Clean Holdings, Inc. (Nasdaq: UCTT), a leading ... for the semiconductor capital equipment, flat panel, medical, ... results for the fourth quarter and fiscal year ... a year of extraordinary growth for UCT. Total ... together with continued focus on operational excellence resulted ...
Breaking Medicine Technology: